UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  SCHEDULE 13D
                    UNDER THE SECURITIES EXCHANGE ACT OF 1934


                              GENERAL DEVICES, INC.
                              ---------------------
                                (Name of Issuer)

                    COMMON STOCK, PAR VALUE $0.0001 PER SHARE
                    -----------------------------------------
                         (Title of Class of Securities)

                                    369514302
                                    ---------
                                 (CUSIP Number)

                               James M. Rae, Esq.
                            Stairs Dillenbeck Finley
                         330 Madison Avenue, 29th Floor
                            New York, New York 10017
                                 (212) 697 2700
                    -----------------------------------------
           (Name, Address and Telephone Number of Person Authorized to
                       Receive Notices and Communications)

                                JANUARY 24, 2006
                                ----------------
             (Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check
the following box. [ ]

NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Section 240.13d-7 for other
parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934, as amended ("Act") or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions of the Act (however, see
the Notes).






CUSIP No. 369514302

1     Names of Reporting Person.
         Norman C. Kristoff
      I.R.S. Identification Nos. of above persons (entities only)
      --------------------------------------------------------------------------
2     Check the Appropriate Box if a Member of a Group (See Instructions)
                                                                        (a) [ ]
                                                                        (b) |X|
      --------------------------------------------------------------------------
3     SEC Use Only
      --------------------------------------------------------------------------
4     Source of Funds (See Instructions)
      PF
      --------------------------------------------------------------------------
5     Check if Disclosure of Legal Proceedings Is Required Pursuant to
      Items 2(d) or 2(e)                                                    [ ]
      --------------------------------------------------------------------------
6     Citizenship or Place of Organization
      USA
      --------------------------------------------------------------------------
                     7    Sole Voting Power             1,521,263 shs.
                          ------------------------------------------------------
  Number of          8    Shared Voting Power           1,024,147 shs.
   Shares                 ------------------------------------------------------
Beneficially         9    Sole Dispositive Power        1,521,263 shs.
   Owned                  ------------------------------------------------------
                    10    Shared Dispositive Power      1,024,147 shs.
                          ------------------------------------------------------
11    Aggregate Amount Beneficially Owned by
      Reporting Person                             2,545,410 shs (1)(2)
      --------------------------------------------------------------------------
12    Check if the Aggregate Amount in Row (11) Excludes Certain Shares
      (See Instructions)                                                    [ ]
      --------------------------------------------------------------------------
13    Percent of Class Represented by Amount in Row (11)    12.6%(1)(2)
      --------------------------------------------------------------------------
14    Type of Reporting Person (See Instructions)
      IN
      --------------------------------------------------------------------------

(1) As described in Item 5 below, the Reporting Person (as defined below) holds
a 50% membership interest in Delphinian Quest Advisors, LLC, a Nevada limited
liability company ("Delphinian"), which owns beneficially 1,079,257 shares of
the Issuer's Common Stock. The other 50% membership interest in Delphinian is
held by Paul T. Chan, and together the Reporting Party and Mr. Chan share the
voting and dispositive powers over the shares of Issuer's Common Stock held by
Delphinian.

(2) The Reporting Person may be deemed to be part of a group pursuant
to the terms of the Stockholders Agreement (as defined below). The Reporting
Person does not affirm to be part of a group and expressly disclaims beneficial
ownership of the shares of Common Stock held by the other parties to the
Stockholders Agreement, with the exception of the 1,079,257 shares owned of
record by Delphinian, referenced above. Accordingly, other than the shares of
Common Stock owned of record by Delphinian, such shares of Common Stock held by
the parties to the Stockholders Agreement are not included in the amounts
specified by the Reporting Person above.



ITEM 1.  SECURITY AND ISSUER

         This Schedule 13D (the "Schedule 13D") relates to shares of common
stock, par value $0.0001 per share (the "Common Stock"), of General Devices,
Inc., a Delaware corporation (the "Issuer"). The address of the principal
executive offices of the Issuer is 153 Greenwood Avenue, Suite 11-13, Bethel,
Connecticut 08640.


ITEM 2.  IDENTITY AND BACKGROUND

         Name of Reporting Person: Norman C. Kristoff (the "Reporting Person")
         Address: 194 Upper Troy Road
                  Fitzwilliam, New Hampshire 03447
         Present Principal Occupation:
                  Private investor and Member of Delphinian Quest
                  Advisors, LLC, (financial consulting)
                  194 Upper Troy Road
                  Fitzwilliam , New Hampshire 03447

         During the past five years, the Reporting Person has not been
         convicted in a criminal proceeding (excluding traffic violations or
         similar misdemeanors).

         During the past five years the Reporting Person has not been a party
         to a civil proceeding of a judicial or administrative body of
         competent jurisdiction which resulted in a judgment, decree or final
         order enjoining future violations of, or prohibiting or mandating
         activities subject to, Federal or State securities laws or finding any
         violation with respect to such laws.

         Citizenship: USA


ITEM 3.  SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

         With the exception of receipt by Delphinian of Issuer's placement agent
warrants covering 165,329 shares of its Common Stock at the time of a merger
("Merger") described below between the Issuer and Aduromed Corporation, a
Delaware corporation ("Aduromed"), the Reporting Person's beneficial interest in
the Common Stock of the Issuer was derived from his beneficial ownership of
shares of common stock of Aduromed received in consideration for financial
consulting and other services rendered by him and Delphinian to Aduromed prior
to the Merger. At the time of the Merger the Reporting Person's beneficial
ownership of Aduromed common stock was converted to beneficial ownership of the
Common Stock of Issuer. No part of the purchase price for those securities were
represented by funds or other consideration borrowed or otherwise obtained for
the purpose of acquiring, holding, trading or voting those Aduromed securities.

         On January 23 2006, pursuant to an Amended and Restated Agreement and
Plan of Merger, dated as of January 23, 2006 (the "Merger Agreement"), by and
among Aduromed, the Issuer and GD Merger Sub, Inc., a Delaware corporation, and
GD Merger Sub II, a Delaware corporation ("MergerSub"): (i) each share of
outstanding common stock of Aduromed, par value $0.01 per share, beneficially
owned by the Reporting Person was converted into 1.795 shares of the Issuer's
shares of Common Stock; and (ii) each warrant to purchase shares of Aduromed's
common stock (the "Aduromed Warrant") beneficially owned by the Reporting Person
was converted into warrants to purchase such number of shares of the Issuer's
Common Stock equal to (A) 1.795 multiplied by (B) the number of shares of common
stock of Aduromed issuable upon exercise of such Aduromed Warrant. The Merger
became effective on January 23, 2006.


ITEM 4.    PURPOSE OF TRANSACTION.

         Issuer's purpose in effecting the Merger was to acquire the business of
Aduromed, which became Issuer's wholly-owned subsidiary, and to facilitate
approximately $5 million funding for Aduromed's



business which closed on January
24, 2006, pursuant to an Amended and Restated Securities Purchase Agreement
dated as of January 23, 2006 (the "Purchase Agreement") by and among Aduromed,
the Issuer and the certain third party funding investors.

         The descriptions of the Merger Agreement and the Purchase Agreement
contained in these Items 3 and 4 are qualified in their entirety by reference to
the Merger Agreement and the Purchase Agreement, which are incorporated herein
by reference as Exhibits 1 and 2, respectively.

STOCKHOLDERS AGREEMENT

         On January 23, 2006, the Issuer and certain stockholders of the Issuer,
including the Reporting Party, Delphinian and those third party investors who
pursuant to the terms of the Purchase Agreement had became holders of Issuer's
Series A Preferred Stock (par value $0.0001 per share) and Issuer's Series B
Preferred Stock (par value $0.0001 per share) (the "Stockholder Parties")
entered into an Amended and Restated Stockholders Agreement (the "Stockholders
Agreement") pursuant to which the Stockholder Parties agreed to vote all
securities of the Issuer owned by such Stockholder Party now or acquired
thereafter at any regular or special meeting of the stockholders of the Issuer
or in any written consent in lieu of a meeting so that (i) the number of
directors of the Issuer will be seven; (ii) for so long as the holders of the
Series A Preferred Stock and the Series B Preferred Stock (the "Preferred
Holders") own at least 10% of the outstanding shares of the Issuer's Common
Stock (calculated as if the Series A Preferred Stock and Series B Preferred
Stock converted into Common Stock and warrants to purchase Common Stock of the
Issuer were exercised) the election to the board of directors (the "Board") of
the Issuer of at least two members designated by the holders of at least a
majority of the outstanding shares of the Series A Preferred Stock and the
Series B Preferred Stock and the appointment to each committee of the Board of
at least one such director designated by the Preferred Holders; (iii) for so
long as Damien Tanaka is employed as the chief executive officer of the Issuer,
the election to the Board of five members designated by Damien Tanaka; and (iv)
the boards of directors of each subsidiary of the Issuer shall be comprised of
the same persons that are from time to time members of the Board. The
stockholders party to the Stockholders Agreement agreed to vote their shares at
any regular or special meeting or in any written consent in lieu of a meeting to
ensure that the Issuer's charter documents do not, at any time, conflict with
the provisions of the Stockholders Agreement.

         Subject to certain exceptions, if the Issuer proposes to issue any
securities, each Preferred Holder has 30 days from the date the Issuer notifies
such Preferred Holder to elect to purchase all of such Preferred Holder's pro
rata share of the securities proposed to be issued at the price and upon the
terms proposed to be offered to the third party. Any such securities that remain
unsubscribed by another Preferred Holder may be purchased on a pro rata basis by
any Preferred Holder that has elected to subscribe for its pro rata share of
such securities. Subject to certain exceptions, the preemptive rights terminate
on date on which the Issuer consummates underwritten public offering of its
Common Stock, with an aggregate price to the public of not less than $50
million, following which, such Common Stock is listed on a national securities
exchange or the National Association of Securities Dealers National Market
System.

         Each stockholder party to the Stockholders Agreement agreed not to
transfer its securities of the Issuer unless the transferee of such securities
agreed in writing to be bound by the terms of the Stockholders Agreement. The
Stockholders Agreement may be amended upon the written consent of the Issuer and
the holders of a majority of the shares held by the stockholders party to the
Stockholders Agreement.

         The Reporting Party intends to comply with his obligations under the
Stockholders Agreement, but otherwise does not intend to act in any managerial
capacity as to the Issuer or Aduromed or to participate in any transaction
having the purpose or effect of changing or influencing the control of Issuer or
Aduromed.


ITEM 5.  INTEREST IN SECURITIES OF THE ISSUER.

         (a)   Beneficially owned:

               2,545,410 shares of Common Stock*




               Percent of class:

                           Based upon the 20,683,239 shares of Common Stock of
                           the Issuer outstanding as of March 10, 2006 (based on
                           Issuer's Form SB-2 filed with the Commission on March
                           24, 2006) the Reporting Person holds approximately
                           12.6%* of the issued and outstanding Common Stock of
                           the Issuer.

         (b)   Number of shares to which Reporting Person has:

               (i)  Sole power to vote or direct the vote:

                                1,521,263 shares*.

               (ii) Shared power to vote or direct the vote:

                                1,024,147 shares*.

               (iii) Sole power to dispose of or to direct the disposition of:

                                1,521,263 shares*.

               (iv)  Shared power to dispose of or direct the disposition of:
                     disposition of:

                                1,024,147 shares.*

               * The Reporting Person beneficially owns an aggregate of
               2,545,410 shares of Common Stock. The foregoing amount of Common
               Stock represents (i) 1,346,250 shares owned of record by the
               Reporting Person, (ii) warrants immediately exercisable to
               purchase 175,012 shares at $0.5571 per share, and (iii) his
               indirect interest in (A) 269,250 shares of record and (B)
               warrants immediately exercisable to purchase 754,897 shares
               (including Placement Agents Warrants covering 165,329 shares)
               held by Delphinian, in which the Reporting Person holds a 50%
               membership interest and Paul C. Chan holds the other 50%
               membership interest. Messrs. Chan and Kristoff together hold the
               entire voting interest in Delphinian and together hold all
               dispositive interest over the shares of Common Stock held by it
               of record, and over the warrants for Common Stock held by it.
               Therefore, for purposes of Rule 13d-3 under the Act, the
               Reporting Person may be deemed to be a beneficial owner of such
               shares.

         (c)   See Item 3 above as to the Merger effected on January 23, 2006,
               whereby all outstanding shares of common stock of Aduromed were
               converted into shares of the Common Stock of Issuer and all
               Aduromed Warrants were converted into warrants of Issuer at a
               conversion rate of 1.795 shares of Issuer's Common Stock for each
               share of Aduromed common stock. It was through this Merger that
               Reporting Party received its beneficial interest in Issuer's
               Common Stock described in paragraph (b) above.


ITEM 6.  CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR.
         RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

         (a)   STOCKHOLDERS AGREEMENT- See discussion in Item 4 above

         (b)   See description of Merger Agreement and the Purchase Agreement
               (Item 3.) and the Stockholders Agreement (Item 4. above). Copies
               thereof are incorporated herein by reference as Exhibits 1, 2,
               and 3, respectively. The descriptions herein of such agreements
               are qualified in their entirety by reference to such agreements


ITEM 7.  MATERIAL TO BE FILED AS EXHIBITS.

         Exhibit 1  Agreement and Plan of Merger, dated January 23, 2006, by and
                    among the Issuer, Aduromed, GD Merger





                    Sub, Inc. and Merger Sub (incorporated by reference to
                    Exhibit 99.2 to the Issuer's Form 8-K/A, dated January 23,
                    2006 (filed January 31, 2006)).

         Exhibit 2  Amended and Restated Securities Purchase Agreement, dated
                    January 23, 2006, by and among the Issuer, Aduromed, the
                    Funds and certain other purchasers parties thereto
                    (incorporated by reference to Exhibit 99.3 to the Issuer's
                    Form 8-K/A, dated January 23, 2006 (filed January 31,
                    2006)).


         Exhibit 3  Amended and Restated Stockholders Agreement, dated January
                    23, 2006, by and among the Issuer and the Stockholder
                    Parties (incorporated by reference to Exhibit 99.5 to the
                    Issuer's Form 8-K/A, dated January 23, 2006 (filed January
                    31, 2006)).




                                S I G N A T U R E

      After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this Schedule 13D is true, complete,
and correct.

Date:  March 29, 2006


                                                    /s/ NORMAN C. KRISTOFF
                                                    ----------------------
                                                    Norman C. Kristoff